close
Prescription drugs

Hundreds of prescription drugs have higher prices in 2022

January 4, 2022 – Pharmaceutical companies raised the prices of hundreds of drugs on January 1, with most prices rising 5% on average.

The prices of 460 drugs have increased, which is in line with that of recent years, according to to STAT News. The start of the New Year is the most popular time for drug companies to raise prices, with more likely to come throughout January.

Several major drugs have been included in this bundle of 2022 price hikes:

  • Gilead: 5.6% on anti-HIV drugs named Biktarvy and Descovy
  • Pfizer: 6.9% on breast cancer drug Ibrance, 6.9% on Prevnar pneumonia vaccine and 4.4% on heart drugs Vyndamax and Vyndaqel
  • Purdue: 5% on the opioid drug OxyContin
  • Vertex: 4.9% on Trikafta, a cystic fibrosis drug that has no competitors and already had a list price of over $ 311,000 per year

In particular, the increases affect the list prices of drugs, according to to Axios. Pharmacy benefit managers can negotiate lower prices for drugs through discounts, so that drug manufacturers can receive lower net prices.

“We expect net prices to continue to decline due to increased rebates and discounts,” a Gilead spokesperson told Axios.

But list prices are still what uninsured people pay, and deductibles and coinsurance rates are often based on a drug’s list price, the outlet reported. Pharmaceutical companies also often earn most of the list price of patented drugs with little competition.

“The modest increase is needed to support investments that allow us to continue to discover new drugs and bring these advances to patients who need them,” a Pfizer spokesperson told Axios.

The price increases for Vertex on Trikafta and other cystic fibrosis drugs are the “first price increases for a Vertex drug since 2017 and the first for… Trikafta,” a spokesperson told Axios.

Pharmaceutical companies did not respond to specific questions about discounts or discounts, the outlet reported.

read more
Medical products

FDA Approves Booster Dose for Teens – Medical Products Supply Chain Weekly Review | Alston & Bird

During the holidays, the CDC updated its recommendations for quarantine and post-exposure masking. The FDA has cleared the booster dose of Pfizer vaccine for adolescents 12 to 15 years old and for immunocompromised children 5 to 11 years old. The FDA has released draft guidelines for manufacturers of medical devices marketed under EUA or enforcement discretion policies to help them transition to traditional approvals at the end of the health emergency. public. The Administration has convened the Supply Chain Disruption Working Group for an update on its progress. The FDA has issued guidance for lab staff and manufacturers on technical considerations for new strains in developing COVID-19 tests and reading current test results. Please see details of these and other supply chain developments below:

  • On December 22, the President convened a meeting of the Supply Chain Disruption Task Force with stakeholders from the business sector. The implementation of the recommendations of the Working Group has led to drastic improvements in the flow of goods in the main ports. Dwell times in the ports of Long Beach and Los Angeles have been reduced from 12 to 5 days and from 9 to 4 days, respectively. The Port of Savannah with the Georgia Ports Authority has set up inland pop-up container sites that are accessible by truck and train, speeding up the movement of containers to these locations. The involvement of commercial carriers has also accelerated the movement of goods through the supply chain. The ports of Long Beach and Los Angeles are still operating towards 24/7 operation.
  • On December 22, administration officials met with EU officials on COVID-19 and global health security to assess each country’s progress towards the goal of the partnership cemented in September to defeat the global pandemic . Increasing the global production of vaccines and supplies is a major component of the initiative. The meeting also focused on developing strategies for future actions, including establishing a source of funding for such efforts.
  • On December 22, the FDA Center for Device and Radiological Health (CDRH) released a draft guidance document “Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUA) During Coronavirus Disease 2019 (COVID-19) Public health emergency ”and“ Transition plan for medical devices that fall under enforcement policies during the public health emergency of coronavirus disease 2019 (COVID-19). These proposed transition plans are guided by the principles of ensuring continued access of patients, providers and consumers to quality products; adequately prepare manufacturers and other stakeholders for the transition; and avoid supply chain disruptions. The plans would provide guidance on the requirements and timelines for marketing presentations. Assessment methods would include a risk-based approach that takes into account the intended uses, regulatory history and the level of risk of the device. A notice will be published for manufacturers 180 days before the expiration date of the EUA declaration. An EUA declaration is separate from a public health emergency declaration. Once an EUA declaration is terminated, all EUAs authorized under the EUA declaration are also terminated. Manufacturers must notify the FDA if they intend to continue marketing their products. The FDA intends to apply a phased approach to products marketed under discretionary enforcement policies that allow manufacturers to prepare for new requirements to avoid disruption. Comments on these draft guidelines are expected by March 23, 2022. We recommend that stakeholders carefully review the documents, submit comments if necessary, and start preparing for transitions early.
  • On December 22, the FDA released a draft guideline, “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,” to provide sponsors and other stakeholders with guidance on how to assess digital health technology (DHT) used in their clinical investigations. The draft guidance includes how to assess a DHT as suitable for use. When evaluating a product, sponsors and stakeholders should consider the rationale for using the product and its descriptions. Sponsors and stakeholders should also consider whether the product can offer verification, validation and usability information. In addition, investigators should determine whether DHT would provide data permitting an appropriate assessment of clinical parameters from the data from any statistical analysis. The draft guidance also emphasizes that risk considerations regarding clinical risks, confidentiality and informed consent should be considered. Comments are due by March 22, 2022.
  • On December 23, the FDA released a revised guideline, “SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests,” which contains specific information regarding the omicron variant. The agency asks labs to be aware that some molecular tests fail to detect omicron and that there are other tests that detect modified omicron. Tests that do not detect omicron should not be used. Laboratories that use tests with multiple genetic targets should be aware that omicron demonstrates genetic abandonment in the results. Although this result may indicate the presence of omicron, it is not definitive. In light of this, the FDA advises labs to consider genetic sequencing if available.
  • On December 27, the CDC announced that it was recommending a five-day window for isolation and the use of masks for asymptomatic people with positive COVID-19 results. The CDC has also changed its recommendations for people exposed to someone with COVID-19 in isolation with strict mask use for five days after exposure for those exposed who are not vaccinated or have been vaccinated more. six months previously (two months for Johnson & Johnson). For those who have received a booster, isolation is not required; however, the use of a mask for five days followed by a test on the fifth day is recommended.
  • On December 29, the Center for Devices and Radiological Health (CDRH) issued an EUA for CLINITEST, a rapid self-test of the COVID-19 antigen from Siemens. This EUA is particularly important because the validation data was collected through the FDA’s collaboration with the National Institutes of Health (ITAP) Independent Testing Assessment Program. SD Biosensor Inc. has also been granted EUA for its home COVID-19 test.
  • On January 3, the FDA announced changes to the EUA for the Pfizer vaccine. The agency decided to allow a booster dose for adolescents 12 to 15 years old and to shorten the recommended time between the primary vaccination and the booster dose to five months, instead of six months. The decision was made on the basis of actual data from Israel which showed no additional security concerns. The decision to reduce the time between the primary series and the booster is taken in response to the prevalence of the more transmissible omicron variant and the need to strengthen the immune response of the population. The FDA has also cleared a third dose of Pfizer vaccine for immunocompromised children 5 to 11 years old. The agency defines immunocompromised as those who have undergone a solid organ transplant or similar conditions that compromise their immune system. The aim is to strengthen their immune response to “enable these children to obtain the maximum potential benefit from the vaccination”.

[View source.]

read more
Medical products

FDA Cleared Booster Dose for Teens – Medical Products Supply Chain Weekly Review – Food, Drugs, Healthcare, Life Sciences

United States: FDA Approves Booster Dose for Teens – Medical Products Supply Chain Weekly Review

To print this article, simply register or connect to Mondaq.com.

During the holidays, the CDC updated its recommendations for quarantine and post-exposure masking. The FDA has cleared the booster dose of Pfizer vaccine for adolescents 12 to 15 years old and for immunocompromised children 5 to 11 years old. The FDA has released draft guidelines for manufacturers of medical devices marketed under EUA or enforcement discretion policies to help them transition to traditional approvals at the end of the health emergency. public. The Administration has convened the Supply Chain Disruption Working Group for an update on its progress. The FDA has issued guidance for lab staff and manufacturers on technical considerations for new strains in developing COVID-19 tests and reading current test results. Please see details of these and other supply chain developments below:

  • On December 22, the President convened a meeting of the Supply Chain Disruption Task Force with stakeholders from the business sector. The implementation of the recommendations of the Working Group has led to drastic improvements in the flow of goods in the main ports. Dwell times in the ports of Long Beach and Los Angeles have been reduced from 12 to 5 days and from 9 to 4 days, respectively. The Port of Savannah with the Georgia Ports Authority has set up inland pop-up container sites that are accessible by truck and train, speeding up the movement of containers to these locations. The involvement of commercial carriers has also accelerated the movement of goods through the supply chain. The ports of Long Beach and Los Angeles are still operating towards 24/7 operation.
  • On December 22, administration officials met with EU officials on COVID-19 and global health security to assess each country’s progress towards the goal of the partnership cemented in September to defeat the global pandemic . Increasing the global production of vaccines and supplies is a major component of the initiative. The meeting also focused on developing strategies for future actions, including establishing a source of funding for such efforts.
  • On December 22, the FDA Center for Device and Radiological Health (CDRH) released a draft guidance document “Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUA) During Coronavirus Disease 2019 (COVID-19) Public health emergency ”and“ Transition plan for medical devices that fall under enforcement policies during the public health emergency of coronavirus disease 2019 (COVID-19). These proposed transition plans are guided by the principles of ensuring continued access of patients, providers and consumers to quality products; adequately prepare manufacturers and other stakeholders for the transition; and avoid supply chain disruptions. The plans would provide guidance on the requirements and timelines for marketing presentations. Assessment methods would include a risk-based approach that takes into account the intended uses, regulatory history and the level of risk of the device. A notice will be published for manufacturers 180 days before the expiration date of the EUA declaration. An EUA declaration is separate from a public health emergency declaration. Once an EUA declaration is terminated, all EUAs authorized under the EUA declaration are also terminated. Manufacturers must notify the FDA if they intend to continue marketing their products. The FDA intends to apply a phased approach to products marketed under discretionary enforcement policies that allow manufacturers to prepare for new requirements to avoid disruption. Comments on these draft guidelines are expected by March 23, 2022. We recommend that stakeholders carefully review the documents, submit comments if necessary, and start preparing for transitions early.
  • On December 22, the FDA released a draft guideline, “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,” to provide sponsors and other stakeholders with guidance on how to assess digital health technology (DHT) used in their clinical investigations. The draft guidance includes how to assess a DHT as suitable for use. When evaluating a product, sponsors and stakeholders should consider the rationale for using the product and its descriptions. Sponsors and stakeholders should also consider whether the product can offer verification, validation and usability information. In addition, investigators should determine whether DHT would provide data permitting an appropriate assessment of clinical parameters from the data from any statistical analysis. The draft guidance also emphasizes that risk considerations regarding clinical risks, confidentiality and informed consent should be considered. Comments are due by March 22, 2022.
  • On December 23, the FDA released a revised guideline, “SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests,” which contains specific information regarding the omicron variant. The agency asks labs to be aware that some molecular tests fail to detect omicron and that there are other tests that detect modified omicron. Tests that do not detect omicron should not be used. Laboratories that use tests with multiple genetic targets should be aware that omicron demonstrates genetic abandonment in the results. Although this result may indicate the presence of omicron, it is not definitive. In light of this, the FDA advises labs to consider genetic sequencing if available.
  • On December 27, the CDC announced that it was recommending a five-day window for isolation and the use of masks for asymptomatic people with positive COVID-19 results. The CDC has also changed its recommendations for people exposed to someone with COVID-19 in isolation with strict mask use for five days after exposure for those exposed who are not vaccinated or have been vaccinated more. six months previously (two months for Johnson & Johnson). For those who have received a booster, isolation is not required; however, the use of a mask for five days followed by a test on the fifth day is recommended.
  • On December 29, the Center for Devices and Radiological Health (CDRH) issued an EUA for CLINITEST, a rapid self-test of the COVID-19 antigen from Siemens. This EUA is particularly important because the validation data was collected through the FDA’s collaboration with the National Institutes of Health (ITAP) Independent Testing Assessment Program. SD Biosensor Inc. has also been granted EUA for its home COVID-19 test.
  • On January 3, the FDA announced changes to the EUA for the Pfizer vaccine. The agency decided to allow a booster dose for adolescents 12 to 15 years old and to shorten the recommended time between the primary vaccination and the booster dose to five months, instead of six months. The decision was made on the basis of actual data from Israel which showed no additional security concerns. The decision to reduce the time between the primary series and the booster is taken in response to the prevalence of the more transmissible omicron variant and the need to strengthen the immune response of the population. The FDA has also cleared a third dose of Pfizer vaccine for immunocompromised children 5 to 11 years old. The agency defines immunocompromised as those who have undergone a solid organ transplant or similar conditions that compromise their immune system. The aim is to strengthen their immune response to “enable these children to obtain the maximum potential benefit from the vaccination”.

The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

POPULAR ARTICLES ON: Food, Medicines, Health Care, Life Sciences of the United States

Alston and Birds Health Care Week in Review, December 17, 2021

Alston & Bird

Below is Alston & Bird’s Healthcare Week review, which provides a summary of the latest healthcare regulatory news, advice and guidance; federal legislation and the work of congressional committees; reports, studies and analyzes; and other health policy news.

read more
Prescription drugs

I became addicted to prescription drugs at 22

I lived in a painless parallel universe where nothing mattered, and had no reason to worry (Photo: Jess Bruno)

Most people don’t view pain relievers as a health hazard, but my addiction to them almost made me fight for my life.

In March 2021, I ended up in hospital after my codeine addiction got out of hand. Ironically, the medication that was supposed to make me feel better made me desperately ill.

I was diagnosed with Crohn’s disease – a chronic condition in which the lining of the digestive system becomes inflamed and often ulcerated – at the age of 18. student in 2011. Sometimes the pain was so bad I couldn’t even get out of bed, let alone go to class. And for the next five years, I barely went into remission.

Somehow I struggled with the almost constant pain, but that all changed in 2016 when I was admitted to the hospital with a particularly nasty flare.

While on the ward, a nurse gave me codeine, an opioid licensed for short-term use in acute pain – and from then on I was addicted.

The codeine made me feel like I was wrapped in cotton. The pain evaporated in 15 minutes, and I felt so calm and in control.

Somehow I persuaded the same nurse to give me a new prescription for 30 mg per day: a relatively low dose to treat the pain, but it was enough to give me relief.

And that was the start of my secret painkiller addiction, a secret craving that lasted for five years.

I felt bad about myself, but my need for pills overshadowed everything else

Soon I wasn’t just taking codeine for Crohn’s pain; I would use it to ease the stress of a tough day or to ease the effects of an argument. And even though I hated to admit it to myself, after six months, I knew I was addicted.

Without realizing it, codeine made me crave alcohol and cigarettes – I guess that’s because the drugs relaxed me so much and put me in a kind of party mood. I drank and smoked to excess, which I knew was terrible for my Crohn’s disease, but I had no control over myself.

Soon I was mixing it with diazepam, a powerful muscle relaxer that I also managed to get on prescription after telling my doctor about the constant and excruciating pain.

When it ran out after eight months, there was still codeine, which was prescribed to me every month.

With the pills, I hardly felt anything. I lived in a painless parallel universe where nothing mattered, and I had no reason to worry. The codeine simply canceled out my physical and emotional angst.

And surprisingly, I kept getting my monthly prescription because the minute I told a doctor or pharmacist that I had a chronic illness, the questions stopped. In a way, that makes me angry, because not enough has been asked.

What I didn’t know at the time was that opioid addiction can cause listlessness, poor judgment, and mood swings.

My excessive addiction to codeine, without even realizing it, caused a spiral in my life.

I didn’t care to plan for the future, and I lived for the day, and was constantly in the open. I neglected my friendships, and I also didn’t care about eating right or exercising.

Worse, I was in such a fog from the pain relievers that I was out of sync with my body, and I couldn’t tell how severe my relapses were.

By the time the pandemic hit, my life was a mess. I spent confinement living with my mother, who has stage four cancer. I’m ashamed to admit that sometimes when the meds weren’t doing the trick, I even pinched the pain relievers she was prescribed. Sure, I felt bad about myself, but my need for pills overshadowed everything else.

It was a secret that I kept to myself because I was too ashamed to confide in anyone else.

What I didn’t know was that consuming too much codeine is terrible for Crohn’s disease because it can cause severe constipation and intestinal blockages, which is exactly what happened to me.

By the time I was admitted to the hospital in March 2021, I was in excruciating agony and had to be sedated.

It wasn’t until then that a doctor read my notes and realized how much codeine I had taken.

I would love to see the NHS create more holistic resources for people with chronic pain

He told me that I could never get another prescription and that I was in dire need of psychiatric addiction support.

It was a brutal reality check, but the awakening I desperately needed.

After two weeks in the hospital, grateful that I was still alive, I vowed to take charge of my life.

I found a life coach and a counselor to help me deal with my emotional issues. And I tested natural ways to manage my pain, like frequent hot baths and using an oversized hot water bottle, which were incredibly effective. I actually feel like a new person.

Sometimes I’m really in agony, but no matter how difficult things get, I won’t let myself go back to my old ways.

Since I quit drugs, my life has only gotten better.

I now live with my boyfriend and set up a small business marketing and social media consulting firm called Jessica Bruno, Social Media Coach. After just seven months, business is booming.

I am also very proactive about my Crohn’s disease, and for the first time in my life, I really take care of myself and try new drugs with the blessing of my doctor.

But it still troubles me how easy it was to get prescribed potentially dangerous drugs. I needed codeine, was in pain, and the initial prescription was completely needed, but it was far too easy for me to keep using it – something I’ll always be ashamed of.

And it looks like I’m not alone: ​​A report from Public Health England in 2020 found that 13% of England’s adult population were prescribed opioid pain relievers.

Earlier this year, the National Institute for Care and Excellence updated its guidelines for treating chronic pain, advising general practitioners not to prescribe opioids to patients as they can be “harmful” and addictive. .

Still, this is only a recommendation, and I can’t help but wonder how many other people are still putting their lives at risk with long-term use of prescription pain relievers.

The pain is very difficult to live with, and codeine can be a life-saving medicine, but it can also be abused. I would love to see the NHS create more holistic resources for people with chronic pain.

There must be a lot more control over people like me, who might also benefit from pain relievers, but who are tempted to abuse them as well. So if you think you have a problem I urge you to say it frankly and talk to your GP.

I can honestly say that I would rather suffer 70% of the time, but fully present and in control of my life, rather than living in a hazy bubble of addiction.

As told to Lucy Benyon.

Do you have a story you would like to share? Contact us by sending an email to [email protected]

Share your views in the comments below.

MORE: I became addicted to drugs at 13

MORE: Does OCD Put You At Higher Risk For Addiction?

MORE: “You never know when you might catch fire”: Young people share what everyday life is like with Crohn’s disease and colitis

read more
Medical supplies

Good Health Will connects medical supplies with those in need – Loveland Reporter-Herald

Renee Juelfs, who works at the Good Health Will store in Loveland, says she has a rewarding job helping people with medical needs.

“I have never had so much fun. I can’t call it work, ”she said recently.

But for people with medical needs, Good Health Will is serious business.

The 501 (c) 3 nonprofit, which has stores in Loveland and Greeley, receives donations of medical supplies and equipment and sells them cheaply to those in need.

The process begins with the members of the community.

Juelfs said that when people no longer need the medical equipment they bought, they often want to find someone else who can benefit from it.

“They hate throwing this wheelchair away,” she said. “They want him to go to someone who needs him.”

Prices may depend on the item and its use. A walker can cost $ 10. A hospital bed can cost $ 200.

For large items, staff can look up the list price and divide it by four, or by two if it’s brand new, out of the box.

Juelfs said that in her six years with Good Health Will, she has seen most clients learn of the nonprofit’s existence either through friends through word-of-mouth or by their doctor’s office.

Sometimes people call from the emergency room to ask if there are black boots available. And sometimes when they have surgery planned, they get a list of the items they’ll need while recovering and come pick them up, Juelfs said.

About 50% of customers who entered the Loveland store in the past month were new to the nonprofit, she said.

Juelfs said the store also maintains an onward payment fund and staff can offer additional discounts if someone can’t afford what they need.

The association helps fill a need of people facing short or long term medical needs and their associated costs, which it can only do with donations from the community.

“There are more and more donations,” Juelfs said.

Katie Diel, deputy director of Good Health Will, answered the following questions for The Reporter-Herald.

1) What services do you offer in northern Colorado?

Good Health Will is a local 501 (c) 3 organization that collects donated medical equipment and health care supplies and offers low cost purchase options for these items to the public at our two retail stores in Loveland and Greeley.

Everyone is welcome to visit our stores from 9 a.m. to 5 p.m. Monday to Friday to donate and / or purchase items. Additionally, we provide pickup and delivery options for bulky and hard-to-move items.

2) Have you seen the needs change during the pandemic, or have the needs changed over the years of activity?

The need for affordable medical equipment and health care supplies has remained constant over the years and even more so during the pandemic.

Fortunately, we continue to receive more donations to meet the needs of our customers.

3) What are the benefits of providing this service?

The greatest reward is seeing relief on our clients’ faces when we can provide a solution to their needs knowing that we have truly helped them during times of stress and uncertainty.


Good Health Will

Years of operation: 15.

Number of employees / volunteers: 12 employees / around 10 volunteers (between the two stores).

Address: 2003 W. Eighth St. in Loveland, and 2393 W. 27th St., Suite 528, in Greeley.

Call: 970-624-6002 in Loveland and 970-515-6935 in Greeley.

Websites: goodhealthwill.org and facebook.com/GoodHealthwill

Good Health Will employee Joey Foncannon assembles a donated hospital bed for testing on Wednesday, December 8, 2021, outside the medical supply thrift store in Loveland. (Jenny Sparks / Loveland Reporter-Herald)
read more
Prescription drugs

An order for the distribution of fake prescription drugs

MANHATTAN, Kansas (WIBW) – After the RCPD warned residents of the dangers of fake prescription drugs and fentanyl on Thursday, a man was arrested for distributing drugs on Friday.

the Riley County Police Department said officers arrested Austin Dowling, 28, of Manhattan, for distributing controlled substances that caused an overdose in April. The alleged substances – Oxycodone and Fentanyl.

RCPD shows the difference between fake and real Oxycodone(RCPD)

The RCPD said an arrest warrant was issued for Dowling during an April 2021 opioid-related overdose investigation in Manhattan.

The officer said he arrested Dowling after he was found driving near the intersection of Valleywood Dr. and Barnes Rd. And was taken into custody just before 11 a.m.

The RCPD said Dowling was arrested on warrant on two counts of distributing possession with intent to distribute a controlled substance, distribution of a controlled substance causing grievous bodily harm and two counts of using a medium. communication for a drug transaction.

Dowling was also arrested on two additional warrants for breach of probation and failure to appear. He is currently confined to Riley Co. jail with a total bond of $ 116,000.

Copyright 2021 WIBW. All rights reserved.

read more
Prescription drugs

2021 Prescription Drug Market Size Analysis by Major Companies and Forecast to 2028

New Jersey, United States, – Market Research Intellect has been analyzing the prescription drug technology and markets since 2018. Since then, through the analysis of company research, we have been very close to the latest research and market developments.

In addition, Market Research Intellect works closely with many clients to help them better understand technology and the market environment and develop innovation and commercialization strategies.

Market Research Intellect offers extensive expertise in analyzing the prescription drug market. We have been in this industry for 20 years and have closely followed the rise and / or fall, success and / or disappointment of many emerging technologies during this time.

This gives us a unique eye of experience when it comes to analyzing emerging technologies in electronic materials. This is very important as it helps to build a realistic market and technology roadmap that reflects the true potential of the technology based on its intrinsic characteristics and the true level of technology and business challenges it faces.

Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=202717

Further, the market revenue by region and country is provided in the Prescription Drugs report. The report’s authors also shed light on common business tactics adopted by players. The major players in the global bPrescription Drugs Market and their complete profiles are included in the report. Additionally, investment opportunities, recommendations, and current trends in the global Prescription Drug market are mapped by the report. As a result of this report, major players in the global Prescription Drugs Market will be able to make right decisions and plan their strategies accordingly to stay ahead of the game.

The competitive landscape is an essential aspect that any key player should be aware of. The report highlights the competitive scenario of the Global Prescription Drug Market to know the competition at the national and global level. The market experts also provided an overview of each major player in the global Prescription Drugs Market, taking into account key aspects such as business areas, production, and product portfolio. Further, the companies in the report are studied on the basis of key factors such as company size, market share, market growth, revenue, production volume, and profit.

The main players covered by the prescription drugs markets:

  • Pfizer
  • rock
  • Sanofi
  • Johnson & johnson
  • Merck & Co. (msd)
  • Novartis
  • Abbvie
  • Gilead Sciences
  • Glaxosmithkline (gsk)
  • Amgen
  • Astrazeneca
  • Bristol-myers Squibb
  • Eli lilly
  • Suits you
  • Bayer
  • Novo Nordisk
  • Allergan
  • Takeda
  • Boehringer Ingelheim
  • Takeda

Prescription Drugs Market Breakdown by Type:

Prescription Drugs Market Split By Application:

The Prescription Drug Market report has been separated into distinct categories such as product type, application, end user, and region. Each segment is rated on the basis of CAGR, share and growth potential. In the regional analysis, the report highlights the potential region, which is expected to generate opportunities in the global Prescription Drug Market in the coming years. This segmental analysis will surely prove to be a useful tool for the readers, stakeholders and market players to get a complete picture of the global Prescription Drugs Market and its growth potential in the coming years.

Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=202717

Scope of Prescription Drugs Market Report

Report attributeDetails
Market size available for years2021 – 2028
Reference year considered2021
Historical data2015 – 2019
Forecast period2021 – 2028
Quantitative unitsRevenue in millions of USD and CAGR from 2021 to 2027
Covered segmentsTypes, applications, end users, etc.
Cover of the reportRevenue forecast, company ranking, competitive landscape, growth factors and trends
Regional scopeNorth America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customizationFree customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
Price and purchase optionsTake advantage of custom shopping options to meet your exact research needs. Explore purchasing options

Regional Prescription Drugs Market Analysis can be represented as follows:

Each regional Prescription Drug industry is carefully studied to understand its current and future growth scenarios. It helps the players to strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and to ensure you stay ahead of the competition.

Based on geography, the global prescription drug market has segmented as follows:

    • North America includes the United States, Canada and Mexico
    • Europe includes Germany, France, UK, Italy, Spain
    • South America includes Colombia, Argentina, Nigeria and Chile
    • Asia-Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

Key questions answered in the report:

  • What is the growth potential of the prescription drug markets?
  • Which product segment will take the lion’s share?
  • Which regional market will emerge as a precursor in the years to come?
  • Which application segment will grow at a sustained rate?
  • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
  • What are the main challenges that the global prescription drug markets could face in the future?
  • Who are the leading companies in the global prescription drug market?
  • What are the main trends that are positively impacting the growth of the market?
  • What are the growth strategies considered by the players to maintain their grip on the global Prescription Drugs market?

For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/prescription-drugs-market-size-and-forecast/

Visualize Prescription Drug Market Using Verified Market Intelligence: –

Verified Market Intelligence is our BI platform for telling the story of this market. VMI provides in-depth predictive trends and accurate insight into over 20,000 emerging and niche markets to help you make key revenue impact decisions for a bright future. VMI provides a comprehensive overview and global competitive landscape by regions, countries and segments, as well as as key players in your market. Present your market reports and findings with built-in presentation capabilities, delivering over 70% of time and resources to investors, sales and marketing, R&D and product development. VMI supports data delivery in interactive Excel and PDF formats and provides over 15 key market indicators for your market.

Visualize the Prescription Drug Market Using VMI @ https: //www.marketresearchintellect.com/mri-intelligence/

The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Prescription Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and. applications. Historical prescription drug distribution data from 2016 to 2020 and forecast to 2021-2029.

About us: Market research intelligence

Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

Contact us:
Mr. Edwyne Fernandes
United States: +1 (650) -781-480
UK: +44 (753) -715-0008
APAC: +61 (488) -85-9400
US Toll Free: +1 (800) -782-1768

Website: –https://www.marketresearchintellect.com/

read more
Medical supplies

Dominican Red Cross donates medical supplies to the National COVID-19 Vaccination Unit

The Dominican Red Cross COVID-19 response program donated medical supplies worth twenty thousand Eastern Caribbean dollars ($ 20,000 XCD) to the National COVID-19 Vaccination Unit. This is to further support the on-going vaccination / immunization program focused on preventing and limiting the further spread of the coronavirus.

The National COVID-19 Vaccination Unit Coordinator, Dr Keevian Burnette, thanked the Dominican Red Cross for contributing items that included syringes, bandages, alcohol prep swabs, among others. Dr Burnette highlighted the enormous support the Ministry of Health has received to date from the Dominican Red Cross since the onset of the disease. He noted that partners and stakeholders like the Dominican Red Cross are making the work of the immunization unit much easier throughout the pandemic.

Speaking on behalf of the Dominican Red Cross, President Reginald Winston noted that since the onset of COVID, the Dominican Red Cross has taken its auxiliary role to the government seriously and has provided support, a education, awareness, relief supplies to help humanity throughout this unprecedented pandemic.

The donation was made at the Dominican Red Cross National Headquarters office in Goodwill on Tuesday 28e December 2021.

read more
Medical products

FDA clears two oral drugs for COVID-19 – Medical Products Supply Chain Weekly Review – Food, Drugs, Healthcare, Life Sciences

United States: FDA clears two oral drugs for COVID-19 – Medical products supply chain review of the week

To print this article, simply register or connect to Mondaq.com.

Last week, the FDA cleared oral antivirals from Pfizer and Merck for the treatment of COVID-19. The Biden-Harris administration released the trucking action plan. The CDC approved the ACIP preference recommendation for the Pfizer-BioNTech and Moderna vaccine boosts. The new recommended Tris vaccine buffer leads to greater stability and does not require dilution. Please see details of these and other supply chain developments below:

  • On December 15, the FDA approved Eagle Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for injection of vasopressin (20 units / ml in multidose vials), a product that has grown in demand during the COVID-pandemic. 19. The FDA said that this approval, the first approval from an ANDA for this product, represents the agency’s commitment “to facilitate access to medical products to help meet the critical needs of the American public.”
  • On December 16, the Authority released its Trucking Action Plan to help reduce supply chain disruption as part of initiatives promoted by the Chain Disruption Task Force. supply. Globally, the plan aims to implement measures to reduce barriers to the issuance of commercial driver’s licenses (CDLs); accelerate the learning of trucking; recruit veterans, especially those with previous trucking experience, into the industry; and schedule listening sessions with the current workforce to implement improvement strategies. In order to promote immediate implementation, the plan also includes specific actions for 30, 60 and 90 days to implement the objectives of the plan.
  • On December 16, the FDA approved the use of Tris buffer for the manufacture of Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. This new formulation offers two key advantages to vaccinators: (1) it increases the stability of the vaccine longer at refrigerated temperatures; and (2) it does not require dilution by the supplier before use.
  • On December 16, the CDC approved the Advisory Committee on Immunization Practices (ACIP) recommendations that the Pfizer-BioNTech and Moderna vaccines are preferred for booster use over the Johnson & Johnson vaccine. ACIP met earlier today and based its decision on data including a review of efficacy and adverse events.
  • On December 17, the FDA announced that it was considering a program that would impose sterilization changes to the master file pilot program for 510 (k) approved medical devices. The change applies to the established Category B or to new sterilization methods. In addition to manufacturers in the innovation challenge, current 510 (k) holders can also participate in two previous programs where the FDA (1) has challenged manufacturers to develop new ways to develop alternatives to the ethylene oxide; and (2) reduce emissions of ethylene oxide. If changes are made to sterilization methods when ethylene oxide is used, participants can now refer to their master files instead of submitting a new 510 (k).
  • On December 20, Moderna announced that it was continuing to advance clinical trials to develop an omicron-specific vaccine for use as a booster. He also noted that the antibodies from his 50mcg and 100mcg booster doses demonstrated a 37- and 83-fold increase in antibody levels. Clinical trials of vaccines targeting both omicron and delta are underway.
  • On December 21, the Center for Devices and Radiological Health (CDRH) released a plan for how the CDRH intends to manage reviewer workload in 2022 based on the increase in the total number of submissions. In 2021, the CDRH saw an increase in medical device submissions for approval through the traditional processes, namely the PMA, 510 (k) and Q-sub processes, which it addressed through the implementation of new approaches to review, including triage of cases, reallocation of staff and resources to COVID-19 products, use of contractors and overtime. Despite these approaches, some issues related to meeting review deadlines still need to be addressed. For devices other than in vitro diagnostics, the CDRH expects to be able to comply with the review deadlines of the Medical Device User Fee Agreement (MDUFA) in 2022 despite the influx of medical products subject to review. For in vitro diagnostic products, the CDRH will also try to meet the deadlines promised by the MDUFA. Non-COVID products that were not prioritized during the pandemic will require extended review times. In addition, the pre-submission request program will be reinstated as of January 1, 2022.
  • On December 22, the FDA cleared Pfizer’s oral antiviral drug, Paxlovid, for the treatment of mild to moderate COVID-19 in adults and children 12 years of age or older (weighing 40 kg or more). This is the first oral antiviral treatment for COVID-19 to receive emergency use authorization. The clearance was based on data from the EPIC-HR trial, which demonstrated that Paxlovid significantly reduced hospitalizations and deaths from all causes in the study population compared to those randomized to receive a placebo. Paxlovid is a combination of nirmatrelvir and ritonavir – the former inhibits the replication of SARS-CoV-2 and the latter slows down the breakdown of nirmatrelvir in the body. The FDA will continue to monitor clinical trial data for the safety and effectiveness of the drug.
  • On December 23, the FDA cleared Merck’s oral antiviral drug, molnupiravir, for the treatment of mild to moderate COVID-19 in adults at high risk of progression to severe COVID-19 and for whom options for Alternative treatment to COVID-19 is not available. accessible or clinically appropriate.

The content of this article is intended to provide a general guide on the subject. Specialist advice should be sought regarding your particular situation.

POPULAR ARTICLES ON: Food, Medicines, Health Care, Life Sciences of the United States

read more
Prescription drugs

Crackdown on the illegal sale of prescription drugs

Police have launched a crackdown on the illegal sale of “prescription drugs” by pharmacies across the state.

Acting on the instructions of the Director General of Police C. Sylendra Babu, special teams from the Narcotics Intelligence Bureau CID as well as officials from the Department of Food Safety and Drug Administration carried out surprise checks in pharmacies in several districts. The aim was to reduce the sale of these drugs without a proper prescription, especially to students and young people.

According to Mahesh Kumar Aggarwal, ADGP, Crime, action has been taken against some pharmacies in the districts of Chengalpattu, Tiruvannamalai, Thanjavur, Salem, Vellore and Tirupattur. Police and the Department of Food Safety and Drug Administration had warned pharmacy owners not to sell over-the-counter “prescription drugs”. Surprise checks would continue, he said. Mr. Aggarwal called on the public to pass on any information about the illegal sale of controlled drugs by calling the hotline 10581 or sending a message via WhatsApp to 949810581. The public can email this contribution to spnibcid @ gmail. com.

In a separate operation, the police conducted a special campaign in all neighborhoods against the sale of narcotics and psychotropic substances. During the operation, over 2,000 kg of ganja and 21 kg of heroin worth approximately 23 crore were seized and 838 accused persons arrested. Some of these suspects had sold contraband to drug addicts. The move follows instructions from Chief Minister Deputy Stalin, who briefed the Assembly on the matter and told officials at a recent meeting that strict measures should be taken to curb the sale of drugs such as ganja near educational institutions, the sources said.

Intervention force

Earlier this week, the national meeting of the Narco Coordination Center Apex Level Committee (NCORD) described drug abuse as a major national security threat that could be addressed with comprehensive coordination between central agencies. and drug control states. The meeting, which was attended by senior police officers from across the country, was asked to form a dedicated anti-narcotics task force, the sources added.

read more
1 2 3 4 10
Page 2 of 10